Intercell AG

euro adhoc: Intercell AG
Financial Figures/Balance Sheet
Intercell announces preliminary Q4 and full-year 2008 results

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

9-month report

02.03.2009

» Increased profitability and strong financial position for full-year 2008 » Excellent progress in late-stage pipeline products » Vaccine to prevent Japanese Encephalitis approved in Australia

Vienna (Austria), March 2, 2009 - Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its preliminary financial results for the fourth quarter and the full financial year 2008, and presented an update on the Company's development programs.

Driven by strong revenues of EUR 30.5 m in the fourth quarter and income tax effects, Intercell´s profit for the full year 2008 was EUR 17.2 m, compared to EUR 5.0 m in the prior year. The annual revenues increased from EUR 53.3 m in the year ended December 31, 2007 to EUR 55.8 m in the year ended December 31, 2008. R&D costs for the full year 2008 increased to EUR 56.1 m and enabled the strong progression of Intercell's late-stage pipeline, including the advanced clinical programs acquired with Iomai Corporation. Cash and marketable securities of EUR 190.9 m at year-end give Intercell a strong financial position and will allow aggressive investment in late-stage pipeline products.

Intercell's vaccine to prevent Japanese Encephalitis, IXIARO®, received positive CHMP opinion in Europe and product approval in Australia, with U.S. approval expected in the near future. No additional requests or comments from the authorities are pending; hence the remaining administrative steps are expected to be concluded soon. "We have successfully managed to market our first vaccine and therefore reached one of the most important milestones in the Company's history - Intercell has proven its ability to develop and produce a product for global markets. With this achievement, we are looking forward to initiating a new growth phase for our company," said Intercell Chief Executive Officer Gerd Zettlmeissl.

DEVELOPMENT PROGRAMS AND PRODUCT PIPELINE

Aggressive investment in four late-stage pipeline products with clinical efficacy results expected within the next 12 months for Travelers Diarrhea vaccine patch, Staphylococcus aureus (S. aureus) vaccine candidate, and Pseudomonas vaccine candidate and Pandemic Influenza

» Traveler's Diarrhea patch vaccine - Recruitment of pivotal Phase III has    begun and initiation of Phase III clinical trial planned for traveling    season in H1 2009

» S. aureus vaccine - Merck & Co., Inc. has advanced the clinical efficacy    trial in cardiothoracic surgery patients and efficacy data is expected mid    2009. The program was expanded with an additional Phase II study in    hemodialysis patients with late-stage kidney disease

» Pseudomonas aeruginosa vaccine - Phase II clinical trial in mechanically    ventilated intensive care patients has been initiated- First efficacy data    is expected H2 2009

» Pandemic Influenza Vaccine Enhancement Patch - Program has been granted    additional funding of USD 12.5 m by U.S. Department of Health and Human    Services (HHS) - Start of Phase II is planned for H1 2009

» Streptococcus pneumoniae vaccine - Phase I clinical trial start with vaccine    candidate to prevent infections with the bacterium Streptococcus pneumoniae    is planned for March 2009

» herapeutic Hepatitis C vaccine - Initiation of next clinical trials will take    advantage of a combination treatment and the use of IC31® as more potent    adjuvant - strategic partnering process ongoing

» Tuberculosis vaccine - Phase I/II clinical development program of Statens    Serum Institut (SSI), Intercell and Sanofi Pasteur is proceeding according    to plan

» Group B Streptococcus vaccine - program has been licensed to Novartis

KEY FINANCIAL INFORMATION

in EUR thousands
                                                      Year ended December 31,
                                            2008                 2007                 2006

Revenues                              55,763              53,349              23,452

Net profit/(loss)                17,175                5,009            (16,143)

Net operating cash flow    (10,186)            41,686              (7,979)

Cash and marketable

securities, end of the
year                                    190,865            287,571              94,421

For the full report please visit www.intercell.com

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: